Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.49 |
| ▸ | NAAA | Q02083 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24938373 | 0.83 | EPHX1 (0.38) | EPHX1NAAAMEN1KMT2AEPHX2 | |
| SCHEMBL18686272 | 0.82 | EPHX1 (0.37) | EPHX1NAAAMEN1KMT2AEPHX2 | |
| SCHEMBL18686104 | 0.81 | ALDH1A1 (0.50) | EPHX1MEN1KMT2AEPHX2SMN1; SMN2 | |
| SCHEMBL18686292 | 0.79 | REN (0.35) | MEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18686112 | 0.79 | ALDH1A1 (0.35) | MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2866869 | 0.78 | EPHX1 (0.65) | EPHX1NAAASMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL18686291 | 0.78 | ALDH1A1 (0.49) | EPHX1NAAAMEN1KMT2AEPHX2 | |
| SCHEMBL21162720 | 0.78 | EPHX1 (0.39) | EPHX1LMNAALDH1A1 | |
| SCHEMBL12820520 | 0.77 | EPHX1 (0.61) | EPHX1NAAASMN1; SMN2ALDH1A1CYP2C19 | |
| SCHEMBL24938407 | 0.76 | KDM4E (0.34) | MEN1KMT2ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4167966-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2023-04-26 | — | — | EP | claimed |
| EP-4167971-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2023-04-26 | — | — | EP | claimed |
| US-20220183977-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2022-06-16 | — | — | US | claimed |
| US-11304906-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | XWPharma Ltd. (KY) | 2022-04-19 | — | — | US | claimed |
| US-20210393537-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | US | claimed |
| WO-2021257886-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | WO | claimed |
| WO-2021257832-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | WO | claimed |
| US-20210393529-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2021-12-23 | — | — | US | claimed |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-09-15 | — | — | US | claimed |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | US | claimed |
| US-20250262157-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2025-08-21 | — | — | US | disclosed |
| US-12337066-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | XWPharma Ltd. (KY) | 2025-06-24 | — | — | US | disclosed |
| EP-4167966-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2023-04-26 | — | — | EP | disclosed |
| EP-4167971-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | XWPharma Ltd. (KY) | 2023-04-26 | — | — | EP | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| WO-2017050259-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12337066-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | GMPS, SI, UGGT1 | EPHX1 2713/4885NAAA 2706/4885MEN1 3670/4885 |
| US-20210393529-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | EPHX1 2713/4885NAAA 2706/4885MEN1 3670/4885 |
| US-20250262157-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | EPHX1 2713/4885NAAA 2706/4885MEN1 3670/4885 |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | EPHX1 964/4885NAAA 431/4885MEN1 3993/4885 |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | EPHX1 964/4885NAAA 431/4885MEN1 3993/4885 |
| US-20210393537-A1 | PHARMACEUTICAL GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, GYS2, SLC18A1 | EPHX1 1846/4885NAAA 2634/4885MEN1 2809/4885 |
| US-20220183977-A1 | CONTROLLED RELEASE GRANULATIONS OF WATER-SOLUBLE ACTIVE PHARMACEUTICAL INGREDIENTS | GMPS, SI, UGGT1 | EPHX1 2713/4885NAAA 2706/4885MEN1 3670/4885 |
| US-11304906-B2 | Controlled release granulations of water-soluble active pharmaceutical ingredients | GMPS, SI, UGGT1 | EPHX1 2713/4885NAAA 2706/4885MEN1 3670/4885 |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | EPHX1 964/4885NAAA 431/4885MEN1 3993/4885 |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | EPHX1 964/4885NAAA 431/4885MEN1 3993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.